As the main effector of TGF-β signaling, SMAD4 has been found to be non-functional in more than half of adenocarcinomas of the pancreatic duct (17–19), and to varying degrees, in several other types of cancers (20–24). This evidence concerns the gene SMAD4 and cancer.